Bone Metastasis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Bone Metastasis - Pipeline Review, H2 2016

Bone Metastasis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Bone Metastasis - Pipeline Review, H2 2016
Published Oct 19, 2016
107 pages — Published Oct 19, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis Pipeline Review, H2 2016, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2, 17 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively for Bone Metastasis.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metast

  
Source:
Document ID
GMDHC8543IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Bone Metastasis Overview91
Therapeutics Development102
  Pipeline Products for Bone Metastasis Overview101
  Pipeline Products for Bone Metastasis Comparative Analysis111
Bone Metastasis Therapeutics under Development by Companies121
Bone Metastasis Therapeutics under Investigation by Universities/Institutes131
Bone Metastasis Pipeline Products Glance143
  Late Stage Products141
  Clinical Stage Products151
  Early Stage Products161
Bone Metastasis Products under Development by Companies171
Bone Metastasis Products under Investigation by Universities/Institutes181
Bone Metastasis Companies Involved in Therapeutics Development1914
  Ablynx NV191
  Alethia Biotherapeutics Inc.201
  Amgen Inc.211
  Amura Holdings Limited221
  Bayer AG231
  BiologicsMD, Inc.241
  ChemoCentryx, Inc.251
  Deciphera Pharmaceuticals, LLC261
  Oncobiologics, Inc.271
  Oncodrone BV281
  Osteologix Holdings Plc.291
  R-Pharm301
  Taiho Pharmaceutical Co., Ltd.311
  Terpenoid Therapeutics Inc321
Bone Metastasis Therapeutics Assessment339
  Assessment by Monotherapy Products331
  Assessment by Target342
  Assessment by Mechanism of Action362
  Assessment by Route of Administration382
  Assessment by Molecule Type402
Drug Profiles4246
  AB-25E9 Drug Profile421
  ADM-01 Drug Profile431
  ALX-0141 Drug Profile442
  AM-3701 Drug Profile461
  AMG-161 Drug Profile471
  BKM-1644 Drug Profile481
  BKM-1740 Drug Profile491
  BMD-3151 Drug Profile501
  CCX-354 Drug Profile512
  DCC-3014 Drug Profile531
  denosumab Drug Profile549
  denosumab biosimilar Drug Profile631
  Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer Drug Profile641
  LG-1980 Drug Profile651
  Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis Drug Profile661
  NBS-101 Drug Profile671
  OCD-155 Drug Profile681
  radium Ra 223 dichloride Drug Profile699
  Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer Drug Profile781
  roneparstat Drug Profile791
  RPH-203 Drug Profile801
  RSF-102 Drug Profile811
  RSF-103 Drug Profile821
  Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology Drug Profile831
  Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology Drug Profile841
  TAS-115 Drug Profile851
  TPH-9 Drug Profile861
  vicrostatin Drug Profile871
Bone Metastasis Dormant Projects883
Bone Metastasis Discontinued Products911
Bone Metastasis Product Development Milestones9214
  Featured News &Press Releases921
    May 18, 2016: Bayer to Showcase Latest Data on Xofigo (radium Ra 223 dichloride) at ASCO 2016921
    Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan931
    Feb 03, 2016: NICE issues full guidance for Xofigoq (radium-223 dichloride)941
    Sep 14, 2015: Bayer to Present Data On Radium-223 Dichloride at ECC2015 in Vienna951
    Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease961
    Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders971
    Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics981
    Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo981
    Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway991
    May 30, 2013: Algeta Announces First Sale Of Xofigo In US1001
    Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium1011
    Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride1021
    Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress1021
    Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders1031
    Jun 04, 2012: Bayer Reports Updated Data From Phase III Study Of Alpharadin For Treatment Of Prostate Cancer1033
Appendix1062
  Methodology1061
  Coverage1061
  Secondary Research1061
  Primary Research1061
  Expert Panel Validation1061
  Contact Us1061
  Disclaimer1071

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Bone Metastasis - Pipeline Review, H2 2016" Oct 19, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bone-Metastasis-Pipeline-Review-H2-2016-2088-16671>
  
APA:
Global Markets Direct - Market Research. (2016). Bone Metastasis - Pipeline Review, H2 2016 Oct 19, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bone-Metastasis-Pipeline-Review-H2-2016-2088-16671>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.